Cytodyn Inc (CYDY)

[finesand]

Maraviroc is not Leronlimab (Pro 140)

so far as we know, Maraviroc blocks the CCR5 receptor completely including its other ligand functionality and this is probably the reason it shows (much more) side effects than PRO 140.

Now PRO 140 seems to keep intact CCR5's other ligand activities, hence almost no sideeffects - but still blocking HIV-1.

Now regarding all the other indications Maraviroc has proven its usage, we only can hope that PRO 140 will works in a similar way.
But it is possible that it just won't and some other indications are achieved by Maraviroc blocking CCR5 ligand operations.

Hope there will be more analysis in this regard.

Back to this undervalued stock price - yes it is undervalued,
as long they almost intentionally miss deadlines and funding goals it is very hard to recovery.